AXIL BRANDS INC (AXIL)

US76151R2067 - Common Stock

4.38  +0.33 (+8.15%)

Fundamental Rating

5

We assign a fundamental rating of 5 out of 10 to AXIL. AXIL was compared to 35 industry peers in the Personal Care Products industry. AXIL has an excellent financial health rating, but there are some minor concerns on its profitability. AXIL is quite expensive at the moment. It does show a decent growth rate.



6

1. Profitability

1.1 Basic Checks

In the past year AXIL was profitable.
In the past year AXIL had a positive cash flow from operations.
The reported net income has been mixed in the past 5 years: AXIL reported negative net income in multiple years.
The reported operating cash flow has been mixed in the past 5 years: AXIL reported negative operating cash flow in multiple years.

1.2 Ratios

AXIL's Return On Assets of 30.37% is amongst the best of the industry. AXIL outperforms 100.00% of its industry peers.
AXIL has a Return On Equity of 43.31%. This is amongst the best in the industry. AXIL outperforms 100.00% of its industry peers.
With an excellent Return On Invested Capital value of 16.32%, AXIL belongs to the best of the industry, outperforming 82.86% of the companies in the same industry.
Industry RankSector Rank
ROA 30.37%
ROE 43.31%
ROIC 16.32%
ROA(3y)9.28%
ROA(5y)-2.18%
ROE(3y)-9.42%
ROE(5y)-29.73%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

AXIL has a Profit Margin of 12.12%. This is amongst the best in the industry. AXIL outperforms 91.43% of its industry peers.
AXIL has a Operating Margin of 5.47%. This is comparable to the rest of the industry: AXIL outperforms 57.14% of its industry peers.
The Gross Margin of AXIL (73.44%) is better than 80.00% of its industry peers.
In the last couple of years the Gross Margin of AXIL has grown nicely.
Industry RankSector Rank
OM 5.47%
PM (TTM) 12.12%
GM 73.44%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y5.09%
GM growth 5Y10.63%

8

2. Health

2.1 Basic Checks

AXIL has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
The number of shares outstanding for AXIL has been increased compared to 1 year ago.
AXIL has more shares outstanding than it did 5 years ago.
AXIL has a better debt/assets ratio than last year.

2.2 Solvency

AXIL has an Altman-Z score of 8.24. This indicates that AXIL is financially healthy and has little risk of bankruptcy at the moment.
AXIL has a better Altman-Z score (8.24) than 85.71% of its industry peers.
AXIL has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 8.24
ROIC/WACC1.88
WACC8.69%

2.3 Liquidity

A Current Ratio of 2.85 indicates that AXIL has no problem at all paying its short term obligations.
AXIL has a better Current ratio (2.85) than 77.14% of its industry peers.
A Quick Ratio of 1.63 indicates that AXIL should not have too much problems paying its short term obligations.
AXIL's Quick ratio of 1.63 is fine compared to the rest of the industry. AXIL outperforms 74.29% of its industry peers.
Industry RankSector Rank
Current Ratio 2.85
Quick Ratio 1.63

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 153.83% over the past year.
The Revenue has grown by 16.91% in the past year. This is quite good.
AXIL shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 94.30% yearly.
EPS 1Y (TTM)153.83%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%284.58%
Revenue 1Y (TTM)16.91%
Revenue growth 3Y156.26%
Revenue growth 5Y94.3%
Sales Q2Q%-5.71%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

2

4. Valuation

4.1 Price/Earnings Ratio

AXIL is valuated rather expensively with a Price/Earnings ratio of 17.52.
Based on the Price/Earnings ratio, AXIL is valued cheaply inside the industry as 82.86% of the companies are valued more expensively.
The average S&P500 Price/Earnings ratio is at 31.46. AXIL is valued slightly cheaper when compared to this.
Industry RankSector Rank
PE 17.52
Fwd PE N/A

4.2 Price Multiples

AXIL's Enterprise Value to EBITDA ratio is a bit cheaper when compared to the industry. AXIL is cheaper than 71.43% of the companies in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 13.94

4.3 Compensation for Growth

AXIL has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

0

5. Dividend

5.1 Amount

AXIL does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

AXIL BRANDS INC

NYSEARCA:AXIL (10/22/2024, 3:00:07 PM)

4.38

+0.33 (+8.15%)

Chartmill FA Rating
GICS SectorConsumer Staples
GICS IndustryGroupHousehold & Personal Products
GICS IndustryPersonal Care Products
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap27.99M
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE 17.52
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 30.37%
ROE 43.31%
ROCE
ROIC
ROICexc
ROICexgc
OM 5.47%
PM (TTM) 12.12%
GM 73.44%
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover2.51
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 2.85
Quick Ratio 1.63
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)153.83%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next YN/A
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)16.91%
Revenue growth 3Y156.26%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y